title: Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure.
abstract: Elevated serum parathyroid hormone (PTH) is an important complicated phenomenon in patients with chronic kidney disease (CKD). Emerging evidence indicates the involvement of PTH in organ fibrosis, and suppression of PTH by cinacalcet (CINA) ameliorates the progression of fibrotic disorders. However, the underlying mechanisms are largely unknown. The endothelial-to-mesenchymal transition (EndMT) has been shown to be an important mechanism involved in renal fibrosis. The present study aimed to investigate whether CINA treatment attenuated renal EndMT in rats with adenine-induced chronic renal failure (CRF). Compared with the control group, serum PTH was significantly higher in the CRF group and was suppressed after CINA treatment. Serum calcium, phosphorus, and calcium × phosphorus product levels were similar in the CRF group and CINA-treated CRF group. Renal collagen accumulation was significantly increased in the CRF group, which was markedly ameliorated by CINA treatment. Expression of the endothelial marker CD31 was significantly downregulated in rats with CRF, whereas expression of the mesenchymal markers fibroblast specific-protein 1 and α-smooth muscle actin was markedly upregulated. These changes were inhibited by CINA treatment. The protein levels of these EndMT-related markers were strongly correlated with serum PTH concentrations. Furthermore, the in vitro study showed that PTH could significantly increase the expression of fibroblast specific-protein 1 and α-smooth muscle actin and decrease CD31 in mRNA and protein levels in a concentration- and time-dependent manner. In conclusion, our study suggests that reducing serum PTH by CINA treatment could attenuate renal fibrosis via suppression of EndMT in the adenine-induced CRF rat model.
authors.affiliation: Institute of Nephrology, Zhongda Hospital, Southeast Univ. School of Medicine, Nanjing 210009, Jiangsu Province, China. liubc64@163.com.
authors.forename: Min
authors.initials: M
authors.lastname: Wu
authors.forename: Ri-Ning
authors.initials: RN
authors.lastname: Tang
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Min
authors.initials: M
authors.lastname: Xu
authors.forename: Ming-Ming
authors.initials: MM
authors.lastname: Pan
authors.forename: Bi-Cheng
authors.initials: BC
authors.lastname: Liu
mesh_terms: D000225:Adenine / Q000633:toxicity*; D000818:Animals; D002454:Cell Differentiation; D002790:Cholesterol 7-alpha-Hydroxylase / Q000235:genetics / Q000378:metabolism; D000069449:Cinacalcet; D042783:Endothelial Cells / Q000166:cytology / Q000502:physiology*; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000201:enzymology; D008297:Male; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000502:physiology*; D009281:Naphthalenes / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000378:metabolism
chemical_list: D009281:Naphthalenes; D012333:RNA, Messenger; C532838:CYP7A1 protein, rat; D002790:Cholesterol 7-alpha-Hydroxylase; D000225:Adenine; D000069449:Cinacalcet
keywords: chronic kidney disease; cinacalcet; endothelial-to-mesenchymal transition; parathyroid hormone; renal fibrosis